source
- FDA issues three new guidances to expand eligibility criteria for cancer trialsThe FDA's Oncology Center of Excellence has released three final guidance documents aimed at widening the pool of patients who can enroll in oncology clinical trials. The guidances focus on three…
- Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drugThe deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.